| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Avi Y. Goldberg last filed a Form 4 in September 2015, as Director at LRMR. Avi Y. Goldberg's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 53,734 shares of LRMR. The LRMR filings lean toward selling, a net 10,000 shares.
Avi Y. Goldberg has 4 Form 4 filings on record from June 2015 to September 2015, all as Director at Larimar Therapeutics (LRMR), 2015.
The 4 reported transactions were 3 open-market sales and 1 option or other derivative award.
Counted by filing, the open-market trades come to no purchases and 3 sales worth about $394K.
The largest open-market sale was 5,000 shares of LRMR at an average $45.00 on September 18, 2015, about $225K.
Shares as reported in the last Form 4 for each company; the most recent is from September 2015. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.